Merck & Co., Inc. (MRK)

NYSE: MRK · Delayed Price · USD
81.38
0.06 (0.07%)
At close: Jan 14, 2022 4:02 PM
81.40
0.02 (0.02%)
After-hours:Jan 14, 2022 7:57 PM EST

Company Description

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health.

The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products.

The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products.

It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers.

The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Synthekine Inc.; and Ridgeback Biotherapeutics. It also has collaboration agreements with Hummingbird Bioscience Pte.

Ltd; Gilead Sciences, Inc. to co-develop and co-commercialize investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; Linnaeus Therapeutics, Inc. to evaluate LNS8801; Biomed X Gmbh for building on ongoing research projects in the fields of oncology and autoimmunity; NGM Biopharmaceuticals, Inc. to focus on the development of medicines in retinal and CVM diseases, as well as to develop and commercialize tests that identify genetic mutations; and IO Biotech ApS to evaluate IO102-IO103.

It also has a partnership with Biocorp Production for the development and supply of Mallya device; and a licensing agreement with The Medicines Patent Pool to facilitate access for molnupiravir, an investigational oral COVID-19 antiviral medicine.

Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Merck & Co., Inc.
Merck & Co. Logo
CountryUnited States
Founded2000
IndustryPharmaceuticals
SectorHealth Care
Employees73,000
CEOKenneth Frazier

Contact Details

Address:
2000 Galloping Hill Rd
Kenilworth, New Jersey 07033-1310
United States
Phone908 740 4000
Websitemerck.com

Stock Details

Ticker SymbolMRK
ExchangeNYSE
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code0000310158

Key Executives

NamePosition
Kenneth C. FrazierExecutive Chairman
Robert M. Davis J.D.President, Chief Executive Officer and Director
Jennifer L. ZacharyExecutive Vice President, General Counsel and Corporate Secretary
Sanat ChattopadhyayExecutive Vice President and President of Merck Manufacturing Division
Caroline LitchfieldExecutive Vice President and Chief Financial Officer
David Michael WilliamsChief Information and Digital Officer
Peter DannenbaumVice President of Investor Relations
Michael W. FlemingSenior Vice President and Chief Ethics and Compliance Officer
Jennifer MauerVice President of Global Communications
Cristal N. DowningExecutive Vice President and Chief Communications and Public Affairs Officer

Latest SEC Filings

DateTypeTitle
Jan 4, 20224Statement of changes in beneficial ownership of securities
Jan 4, 20224Statement of changes in beneficial ownership of securities
Jan 4, 20224Statement of changes in beneficial ownership of securities
Jan 4, 20224Statement of changes in beneficial ownership of securities
Dec 10, 20218-KCurrent report
Dec 9, 2021424B5Prospectus [Rule 424(b)(5)]
Dec 7, 2021FWPFiling under Securities Act Rules 163/433 of free writing prospectuses
Dec 7, 2021424B5Prospectus [Rule 424(b)(5)]
Nov 10, 20214Statement of changes in beneficial ownership of securities
Nov 5, 20214Statement of changes in beneficial ownership of securities
View All SEC Filings